Prophylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1β production via NRF2-mediated counter-regulation of the inflammasome
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Rheumatoid arthritis (RA) remains a debilitating autoimmune condition as many patients are refractory to existing conventional and biologic therapies, and hence successful development of novel treatments remains a critical requirement. Towards this, we now describe a synthetic drug-like small molecule analogue, SMA-12b, of an immunomodulatory parasitic worm product, ES-62, which acts both prophylactically and therapeutically against collagen-induced arthritis (CIA) in mice. Mechanistic analysis revealed that SMA-12b modifies the expression of a number of inflammatory response genes, particularly those associated with the inflammasome in mouse bone marrow-derived macrophages and indeed IL-1β was the most down-regulated gene. Consistent with this, IL-1β was significantly reduced in the joints of mice with CIA treated with SMA-12b. SMA-12b also increased the expression of a number of genes associated with anti-oxidant responses that are controlled by the transcription factor NRF2 and critically, was unable to inhibit expression of IL-1β by macrophages derived from the bone marrow of NRF2(-/-) mice. Collectively, these data suggest that SMA-12b could provide the basis of an entirely novel approach to fulfilling the urgent need for new treatments for RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414 · cited 1×
“For example, whilst IL-17 is secreted in high levels during the initiation phase of arthritis, this production is much reduced at the chronic stage [82].”
BackgroundThe Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer
Kansanen, E., Kuosmanen, S. M., Leinonen, H., & Levonen, A.-L. (2013) · Redox Biology · doi:10.1016/j.redox.2012.10.001 · Cited by 1,313 · cited 1×
“The 12b-derived vinyl sulfone, as an electrophile, could in theory interact with thiolgroups on cysteine residues of the NRF2 repressor protein, Keap-1, and based on recent ideas reported in the literature [45] this could cause a conformational change that would allow release of NRF2, and translocation to the nucleus…”
BackgroundActivation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis
Li, W., Khor, T. O., Xu, C., Shen, G., Jeong, W.-S., Yu, S., & Kong, A.-N. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.017 · Cited by 738
Obesity in autoimmune diseases: Not a passive bystander
Versini, M., Jeandel, P.-Y., Rosenthal, E., & Shoenfeld, Y. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.07.001 · Cited by 694
Toward clinical application of the Keap1-Nrf2 pathway
Suzuki, T., Motohashi, H., & Yamamoto, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.005 · Cited by 680 · cited 1×
“At the same time, IPA indicated activation of NRF2; a key component of the response to oxidative stress [40,41].”
BackgroundAl-Riyami, L., Pineda, M. A., Rzepecka, J., Huggan, J. K., Khalaf, A. I., Suckling, C. J., Scott, F. J., Rodgers, D. T., Harnett, M. M., & Harnett, W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401251p · Cited by 94
Self-citationPhosphorylcholine mimics the effects of ES-62 on macrophages and dendritic cells
GOODRIDGE, H. S., McGUINESS, S., HOUSTON, K. M., EGAN, C. A., AL‐RIYAMI, L., ALCOCER, M. J. C., HARNETT, M. M., & HARNETT, W. (2007) · Parasite Immunology · doi:10.1111/j.1365-3024.2006.00926.x · Cited by 89
Self-citationNeidhart (2000) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200012)43:12 · Cited by 1
Cited by
Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis
Chen, Z., Bozec, A., Ramming, A., & Schett, G. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0109-2 · Cited by 719
The hygiene hypothesis in autoimmunity: the role of pathogens and commensals
Bach, J.-F. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.111 · Cited by 515
Zeng, J., Chen, Y., Ding, R., Feng, L., Fu, Z., Yang, S., Deng, X., Xie, Z., & Zheng, S. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0895-5 · Cited by 319
The Crosstalk between Nrf2 and Inflammasomes
Hennig, P., Garstkiewicz, M., Grossi, S., Di Filippo, M., French, L., & Beer, H.-D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020562 · Cited by 253
Doonan, J., Lumb, F. E., Pineda, M. A., Tarafdar, A., Crowe, J., Khan, A. M., Suckling, C. J., Harnett, M. M., & Harnett, W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01016 · Cited by 38
Self-citation
Metadata
- Authors
- Rzepecka, J., Pineda, M. A., Al-Riyami, L., Rodgers, D. T., Huggan, J. K., Lumb, F. E., Khalaf, A. I., Meakin, P. J., Corbet, M., Ashford, M. L., Suckling, C. J., Harnett, M. M., & Harnett, W.
- Venue
- Journal of Autoimmunity
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 60
- Pages
- 59-73
- ISSN
- 0896-8411 (ISSN-L)
- OpenAlex
- W2135035136
- Cited by
- 76
- References
- 9
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.